ArticleScientific reports2025
Identify novel molecular subtypes of lung adenocarcinoma to predict treatment response and prognosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This study aimed to establish a novel quantification system of anoikis and angiogenesis related genes (AAGs) and comprehensively analyze the relationship between AAG signature score (AAGscore) and the prognosis, tumor immune microenvironment, and therapeutic response in LUAD. Univariate Cox regression analysis was used to screen prognosis-related AAGs. A consensus clustering algorithm was applied for AAG subtypes identification on 750 LUAD samples from TCGA and GEO databases. The differences in prognosis, immune infiltration, and therapeutic response were evaluated among the subtypes. The AAG signature scoring system was constructed by a principal component analysis algorithm. Cluster-A demonstrated a high gene expression and stromal-score with a poor prognosis. Our results showed that there were significant differences in survival time, mutation frequency, expression of chemokines and receptors, expression of immune checkpoint related genes, immunotherapy efficacy and antitumor drug sensitivity between high- and low-AAGscore groups. Survival analysis revealed that patients in the high-AAGscore group had better prognosis. We also discovered that the AAGcluster-B and geneCluster-2 subtype showed higher AAGscores. In addition, a number of conventional antitumor drugs were selected to test the sensitivity of high- and low-AAGscore groups to drug therapy. In summary, we constructed molecular subtypes and AAGscores of LUAD based on AAGs. The risk score model can be used to predict the prognosis of LUAD patients and the efficacy and sensitivity of antitumor drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.